Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Infant Bacterial Therapeutics AB (9IB) Stock Price & Analysis

9IB Stock Chart & Stats

€5.94-€0.15(-2.46%)
At close: 5:30 PM GMT+1
EUR 6.5EUR 7EUR 7.56 Oct22 Oct
Day’s Range
EUR 5.94 - EUR 6.16
52-Week Range
EUR 3.91 - EUR 7.53
Previous Close
EUR 6.09
Volume
0
Average Volume (3M)
34
Market Cap
EUR 80.38M
Enterprise Value
EUR 834.40M
Total Cash (Recent Filing)
EUR 108.60M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
-0.23
Next Earnings
Nov 13, 2026 (Est.)
EPS Estimate
-0.24
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of debt reduces interest obligations and refinancing exposure while the company funds clinical development. This provides greater financial flexibility than a leveraged biotech, although it does not remove the need for future financing while programs remain pre-commercial.

Moderating Cash Burn

The reduction in negative operating and free cash flow suggests some spending moderation as development continues. If maintained, lower burn could extend financial flexibility and make future funding more efficient, even though the company has not yet reached cash generation.

Focused Infant Microbiome Platform

A focused platform addressing serious conditions in preterm infants can support specialized clinical expertise and a differentiated product position if efficacy is demonstrated. The lead program’s defined medical objective gives development efforts a coherent strategic direction.

Bears Say

No Commercial Revenue

The absence of product revenue confirms that the business has not yet reached commercialization and has no established recurring sales base. Future economic value therefore depends on successful clinical development, regulatory approval, and eventual commercialization or partnering.

Persistent Operating Losses

Large continuing losses show that operating expenses and development spending substantially exceed current income. This weak earnings profile can persist until a candidate is commercialized or partnered, limiting internal reinvestment capacity and increasing dependence on strategic execution.

Equity Erosion And Funding Dependence

Material equity erosion reflects the cumulative effect of losses and cash consumption, reducing the financial base available to support development. Continued reliance on external funding may create dilution pressure and constrain the company’s ability to finance programs independently.

Infant Bacterial Therapeutics AB News

9IB FAQ

What was Infant Bacterial Therapeutics AB’s price range in the past 12 months?
Infant Bacterial Therapeutics AB lowest stock price was €3.91 and its highest was €7.53 in the past 12 months.
What is Infant Bacterial Therapeutics AB’s market cap?
Infant Bacterial Therapeutics AB’s market cap is €80.38M.
When is Infant Bacterial Therapeutics AB’s upcoming earnings report date?
Infant Bacterial Therapeutics AB’s next earnings report is estimated for Nov 13, 2026 (not yet confirmed), which is in 12 days.
How were Infant Bacterial Therapeutics AB’s earnings last quarter?
Infant Bacterial Therapeutics AB released its earnings results on Aug 26, 2026. The company reported -€0.201 earnings per share for the quarter, missing the consensus estimate of -€0.142 by -€0.059.
Is Infant Bacterial Therapeutics AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Infant Bacterial Therapeutics AB pay dividends?
Infant Bacterial Therapeutics AB does not currently pay dividends.
What is Infant Bacterial Therapeutics AB’s EPS estimate?
Infant Bacterial Therapeutics AB’s EPS estimate is -0.24.
How many shares outstanding does Infant Bacterial Therapeutics AB have?
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics AB’s price movement after its last earnings report?
Infant Bacterial Therapeutics AB reported an EPS of -€0.201 in its last earnings report, missing expectations of -€0.142. Following the earnings report the stock price went up 2.838%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics AB?
Currently, no hedge funds are holding shares in DE:9IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology